- Posted March 11, 2013 by
St. Louis, Missouri
- New Organization Aims to Reduce Violence in “Hot Spot” Crime Areas
- Waste Management of Illinois Awards Green School Coordinator of the Year Award to Marcie Young
- City of O’Fallon Receives Environmental Excellence Award from St. Clair County
- Threes are Wild
- HBO’s Margaret Judson Tapped to Host 37th Annual Mid-America EMMY® Awards
Mobius Therapeutics™ Receives Payment Indicator for Reimbursement of Mitosol®
“This is a substantial milestone and confirms the inherent value represented by Mitosol®,” said Ed Timm, President of Mobius Therapeutics. “In light of the on-going concerns related to the sterility and quality assurance of compounded medications, this will give providers and patients peace of mind, knowing that the precision, safety, and convenience of Mitosol® is also the wise economic choice.”
J-codes are part of the Health Common Procedure Coding System (HCPCS) and are used by providers to identify drugs and facilitate their reimbursement. These codes are acknowledged by Medicare and most private insurance carriers.
“This further validates the inherent value of FDA approved formulations versus compounded medications,” continued Timm. ” In the end, everyone wins: the patient, the provider, and the American healthcare system.”
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.